Enlivex Therapeutics Ltd. (ENLV.TA)
ILA 330.6
(-0.57%)
ILA 330.6
(-0.57%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 219 Thousand USD | 100.46% |
| 2022 | -47.16 Million USD | -345.62% |
| 2021 | -10.58 Million USD | -93.51% |
| 2020 | -5.47 Million USD | -43.01% |
| 2019 | -3.82 Million USD | 60.71% |
| 2018 | -9.73 Million USD | -176.12% |
| 2017 | -3.52 Million USD | 48.68% |
| 2016 | -6.87 Million USD | 5.7% |
| 2015 | -7.28 Million USD | 31.15% |
| 2014 | -10.58 Million USD | -90.68% |
| 2013 | -5.55 Million USD | -3701.37% |
| 2012 | -146 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.91 Million USD | -195.63% |
| 2024 Q1 | -985 Thousand USD | -549.77% |
| 2023 FY | 219 Thousand USD | 100.46% |
| 2023 Q1 | -8.46 Million USD | 82.06% |
| 2023 Q4 | 219 Thousand USD | -91.41% |
| 2023 Q3 | 2.54 Million USD | 179.69% |
| 2023 Q2 | 911 Thousand USD | 110.77% |
| 2022 Q3 | -33.29 Million USD | -70.54% |
| 2022 Q4 | -47.16 Million USD | -41.68% |
| 2022 FY | -47.16 Million USD | -345.62% |
| 2022 Q1 | -66.97 Million USD | -532.71% |
| 2022 Q2 | -19.52 Million USD | 70.85% |
| 2021 Q2 | -12.4 Million USD | -219.31% |
| 2021 FY | -10.58 Million USD | -93.51% |
| 2021 Q1 | -3.88 Million USD | 28.99% |
| 2021 Q4 | -10.58 Million USD | 50.79% |
| 2021 Q3 | -21.51 Million USD | -73.44% |
| 2020 Q2 | -9.8 Million USD | 56.52% |
| 2020 FY | -5.47 Million USD | -43.01% |
| 2020 Q3 | -3.46 Million USD | 64.65% |
| 2020 Q4 | -5.47 Million USD | -57.82% |
| 2020 Q1 | -22.54 Million USD | -489.46% |
| 2019 Q3 | -5.44 Million USD | 62.55% |
| 2019 FY | -3.82 Million USD | 60.71% |
| 2019 Q4 | -3.82 Million USD | 29.79% |
| 2019 Q2 | -14.54 Million USD | -6.64% |
| 2019 Q1 | -13.64 Million USD | -40.12% |
| 2018 Q2 | -1.67 Million USD | -118.59% |
| 2018 Q3 | -11.35 Million USD | -578.08% |
| 2018 Q4 | -9.73 Million USD | 14.23% |
| 2018 FY | -9.73 Million USD | -176.12% |
| 2018 Q1 | 9 Million USD | 355.39% |
| 2017 FY | -3.52 Million USD | 48.68% |
| 2017 Q3 | -4.1 Million USD | 20.49% |
| 2017 Q4 | -3.52 Million USD | 14.1% |
| 2017 Q1 | -4.1 Million USD | 40.33% |
| 2017 Q2 | -5.16 Million USD | -25.93% |
| 2016 Q3 | -5.92 Million USD | 32.03% |
| 2016 Q2 | -8.71 Million USD | 8.52% |
| 2016 Q1 | -9.52 Million USD | -30.74% |
| 2016 FY | -6.87 Million USD | 5.7% |
| 2016 Q4 | -6.87 Million USD | -16.01% |
| 2015 Q3 | -4.94 Million USD | 45.77% |
| 2015 Q4 | -7.28 Million USD | -47.28% |
| 2015 FY | -7.28 Million USD | 31.15% |
| 2015 Q2 | -9.12 Million USD | -30.11% |
| 2015 Q1 | -7.01 Million USD | 33.75% |
| 2014 Q4 | -10.58 Million USD | 68.99% |
| 2014 Q3 | -34.12 Million USD | -704.34% |
| 2014 Q2 | -4.24 Million USD | 0.0% |
| 2014 FY | -10.58 Million USD | -90.68% |
| 2013 Q4 | -5.55 Million USD | 0.0% |
| 2013 FY | -5.55 Million USD | -3701.37% |
| 2012 FY | -146 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Matricelf Ltd | -835 Thousand ILA | 126.228% |